NINLARO (ixazomib)
ORAL ADMINISTRATION
Indications for Prior Authorization:
- Multiple myeloma
All of the following must be met as a condition for coverage:
- Treatment of multiple myeloma (in combination with lenalidomide and dexamethasone) in patients who have received at least 1 prior therapy
This Medication is Not Approvable for the following condition(s).
- Any condition not listed above as an approved indication
Dosing:
- 4 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle (in combination with lenalidomide and dexamethasone)
- Continue until disease progression or unacceptably toxicity
Approval:
One Year
Last review date: July 25, 2016